Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $20
Carlsmed, Inc.
Carlsmed, Inc. CARL | 0.00 |
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:
CARL) with a Buy and raises the price target from $18 to $20.
